Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Edgewise Therapeutics, Inc. Clear all
Active, not recruiting Phase 2 Interventional

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

NCT05291091
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

NCT07456059
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in People With Renal Impairment

NCT07034768
View directory record Official record
Conditions
Renal Impairments
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Active, not recruiting No phase listed Observational

Defining Endpoints in Becker Muscular Dystrophy

NCT05257473
View directory record Official record
Conditions
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

NCT06738836
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDG-15400 in Healthy Adults

NCT07177066
View directory record Official record
Conditions
Healthy Adults
Interventions
EDG-15400, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

NCT06347159
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

NCT06100887
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Sacramento, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 1, 2026, 9:45 AM EDT
Enrolling by invitation Phase 2 Interventional

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

NCT06066580
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Sevasemten
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
24
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Results available

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

NCT05160415
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Sevasemten
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

NCT05730842
View directory record Official record
Conditions
Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn
Interventions
EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616
View directory record Official record
Conditions
Hepatic Impairment (HI)
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

NCT06916897
View directory record Official record
Conditions
Healthy Subjects
Interventions
sevasemten, Verapamil
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling

NCT05492734
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
EDG-5506
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 1, 2026, 9:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults

NCT04585464
View directory record Official record
Conditions
Healthy Volunteer, Becker Muscular Dystrophy
Interventions
EDG-5506, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDG-7500 in Healthy Adults

NCT06011317
View directory record Official record
Conditions
Healthy Subjects
Interventions
EDG-7500, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 1, 2026, 9:45 AM EDT
Recruiting Phase 2 Interventional

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

NCT07795814
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
30 Years to 84 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 9:45 AM EDT